SS Innovations International, Inc. (NASDAQ: SSII) has reported robust growth in the adoption of its SSi Mantra surgical robotic system, signaling increasing global demand for cost-effective robotic surgery solutions. As of September 8, 2026, cumulative procedures performed using the SSi Mantra reached 14,103, a 79% increase from 7,885 at the end of 2025. The installed base of systems grew 42% to 238 units, up from 168, reflecting accelerating adoption across hospitals worldwide.
The SSi Mantra is now installed in 12 countries, with approximately 1,500 physicians trained on the platform. The system has been used for more than 170 types of surgical procedures, underscoring its versatility. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the first installation of an SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the company's success in penetrating diverse markets and expanding the reach of robotic surgery beyond traditional high-income settings.
In addition to adult procedures, SS Innovations reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of August 31. Notably, a telesurgery was performed over a distance of more than 13,600 miles between Colombia and India, demonstrating the system's capability for remote surgery across continents. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, showcasing the platform's efficiency and potential for high-volume adoption.
The company anticipates key regulatory milestones that could further propel growth. SS Innovations expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. Additionally, the company believes European Union CE marking certification can be obtained by year-end 2026. These approvals would open up two of the largest medical device markets, significantly expanding the addressable market for SSi Mantra and potentially accelerating revenue growth.
SS Innovations, an American company headquartered in India, aims to make robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the SSi Mantra system and the SSi Mudra suite of surgical instruments, which support a variety of procedures including cardiac surgery. The company's focus on cost-effective solutions positions it to address unmet needs in both developed and emerging markets.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. For a full report on the company's progress, visit https://ibn.fm/DJILj. These resources provide investors with additional context on the company's trajectory and market opportunities.
The strong procedure and installation growth, combined with upcoming regulatory decisions, could position SS Innovations as a significant player in the global surgical robotics market. If the company secures FDA clearance and CE marking, it may challenge established competitors by offering a more affordable alternative, potentially disrupting the market and driving further adoption. The expansion into telesurgery and pediatric applications also demonstrates the platform's potential to address a wide range of surgical needs, which could lead to broader acceptance among healthcare providers.
